Advances of Cancer Therapy by Nanotechnology
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Conventional chemotherapeutic drugs are distributed nonspecifically in the body where they affect both cancerous and healthy cells, resulting in dose-related side effects and inadequate drug concentrations reaching the tumor.Non-specific drug delivery leads to significant complications that represent a serious obstacle to effective anticancer therapy.In addition, the occurrence of resistance phenomena reduces the efficacy of cancer treatment.To overcome the lack of specificity of conventional chemotherapeutic drugs, several ligand-targeted therapeutic strategies, including immunotoxins, radioimmunotherapeutics, and drug immunoconjugates, are being developed.Although these conjugated agents have shown promising efficacy compared with conventional chemotherapy drugs, limitations in their delivery efficiency still remain.Recent progress in cancer nanotechnology raises exciting opportunities for specific drug delivery.Nanoparticles, particularly in the size range from 10 nm to 100 nm, are emerging as a class of therapeutics for cancer treatment.Nanoparticles can be composed of several functional molecules simultaneously, such as small molecule drugs, peptides, proteins, and nucleic acids.By using both passive and active targeting strategies, nanoparticles can increase the intracellular concentration of drugs in cancer cells while minimizing toxicity in normal cells; thereby enhancing anticancer effects and reducing systemic toxicity simultaneously, when compared with the therapeutic entities they contain.Furthermore, nanoparticles offer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Self-citationIn vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201
Self-citationKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
Nanocarriers for drug delivery applications
Chamundeeswari, M., Jeslin, J., & Verma, M. L. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-018-00841-1 · Cited by 444
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
BAZAK, R., HOURI, M., ACHY, S. E., HUSSEIN, W., & REFAAT, T. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.356 · Cited by 435
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Kumar, S., Rani, R., Dilbaghi, N., Tankeshwar, K., & Kim, K.-H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00517a · Cited by 397
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin
Aqil, F., Munagala, R., Jeyabalan, J., Agrawal, A. K., & Gupta, R. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0154-9 · Cited by 306
Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective
Davatgaran-Taghipour, Y., Masoomzadeh, S., Farzaei, M. H., Bahramsoltani, R., Karimi-Soureh, Z., Rahimi, R., & Abdollahi, M. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131973 · Cited by 281
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Targeted photodynamic therapy — a promising strategy of tumor treatment
Bugaj, A. M. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c0pp00147c · Cited by 253
Liposomes as Potential Drug Carrier Systems for Drug Delivery
Çağdaş, M., Sezer, A. D., & Bucak, S. (2014) · Application of Nanotechnology in Drug Delivery · doi:10.5772/58459 · Cited by 245
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.006 · Cited by 183
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Saddik, M. S., Elsayed, M. M. A., Abdelkader, M. S. A., El-Mokhtar, M. A., Abdel-Aleem, J. A., Abu-Dief, A. M., Al-Hakkani, M. F., Farghaly, H. S., & Abou-Taleb, H. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020226 · Cited by 89
Yanar, F., Carugo, D., & Zhang, X. (2023) · Molecules · doi:10.3390/molecules28155694 · Cited by 80
“NPs can also be subject to rapid clearance due to opsonization by serum proteins, whereby liposomes become recognizable by the immune system and can be digested by macrophages of the reticuloendothelial system (RES) [17], especially in the liver and spleen, resulting in lowered therapeutic efficacy overall.”
BackgroundInfluential
Metadata
- Authors
- Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M.
- Venue
- Cancer Research and Treatment
- Publisher
- Korean Cancer Association
- Published
- 2009
- Volume
- 41
- Issue
- 1
- Pages
- 1
- ISSN
- 1598-2998 (ISSN-L)
- OpenAlex
- W1970720922
- Cited by
- 230
- References
- 14
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.